Integrated animal models, detection assays and custom services support pre-clinical diabetes translational studies

HUSTON, TX, UNITED STATES, November 16, 2026 /EINPresswire.com/ — Observed annually on November 14, World Diabetes Day raises global awareness of diabetes prevention, management and complications. Driven by rising prevalence worldwide, pre-clinical diabetes research demands reliable animal disease models and well-validated biological reagents. Cloud-Clone Corp. delivers an end-to-end research toolkit spanning mechanistic investigation, biomarker detection, animal modelling and custom services to support scientists exploring diabetes and associated metabolic disorders.
World Diabetes Day was co-launched in 1991 by the International Diabetes Federation (IDF) and the World Health Organization (WHO), commemorating the birthday of Frederick Banting, the discoverer of insulin. Its well-known blue-circle logo symbolizes life, health and global solidarity. According to IDF statistics, more than 500 million adults are living with diabetes globally, and patient numbers are projected to keep increasing in coming decades. Beyond hyperglycaemia itself, disabling or life-threatening complications including nephropathy, retinopathy, neuropathy, diabetic foot lesions and cardiovascular events represent the major clinical burden of diabetes. While public-health strategies emphasize lifestyle modification and regular screening, basic and translational research focuses on unravelling insulin resistance, pancreatic β-cell failure and developing therapies to slow complication progression. Such research heavily depends on robust experimental systems recapitulating human pathological features.
Diabetes is categorized into type 1, type 2, gestational diabetes and rare special-interest forms; type 2 diabetes accounts for over 90 % of clinical cases. Its core pathology combines insulin resistance and progressive β-cell dysfunction, accompanied by chronic low-grade inflammation, lipid dysregulation, oxidative stress and accumulation of advanced glycation end-products (AGEs). Given its slow progression and multi-organ complications, no purely in-vitro system can fully recapitulate systemic disease crosstalk. Animal models therefore serve as indispensable platforms for mechanistic dissection and pre-clinical drug evaluation.
Widely adopted diabetic pre-clinical models include:
Spontaneous type 2 diabetic models: db/db mice, ob/ob mice, ZDF rats, GK rats and KK-Ay mice, which spontaneously develop hyperglycaemia, obesity, insulin resistance and β-cell impairment resembling human type 2 diabetes.
Chemically-induced models: High-dose streptozotocin (STZ) selectively destroys pancreatic β-cells for type 1 diabetes studies; low-dose STZ combined with high-fat diets mimics glucolipotoxicity in type 2 diabetes.
Diet-induced models: High-fat/high-sugar diet-triggered obesity, insulin resistance and fatty-liver phenotypes for studying lifestyle-related metabolic disturbances.
Complication models: Established from long-term diabetic animals to investigate nephropathy, retinopathy, peripheral neuropathy and impaired wound-healing.
Comorbidity models: ApoE-knockout-based atherosclerosis, non-alcoholic fatty liver disease and osteoporosis for studying diabetic crosstalk with other disorders.
High-quality diabetic models require stable, reproducible read-outs including blood-glucose curves, body-weight dynamics, insulin secretion and complication manifestations. Long modelling timelines and substantial inter-individual variation demand specialized expertise and strict quality-control frameworks.
Cloud-Clone operates large-scale SPF-grade animal facilities and experienced modelling teams to generate hundreds of human-disease animal models covering metabolism, cardiovascular science, neuroscience and oncology. For diabetes-focused projects, standard or custom-built models include STZ-induced diabetes, high-fat-diet-driven insulin resistance and multiple diabetic-complication phenotypes. The company provides comprehensive quality control for blood glucose, body weight, glucose-tolerance profiles and pathological endpoints. Complementary in-vivo services cover behavioural assays, in-vivo imaging, histopathological processing (H&E, Masson, Oil-Red-O, immunohistochemistry and immunofluorescence), and multi-time-point tissue and bio-sample collection to generate publication-ready datasets.
Cloud-Clone’s reagent portfolio includes ELISA kits, recombinant proteins and antibodies across human, mouse, rat and rabbit species, covering major analytical branches of diabetes research:
Core glycometabolism markers: Insulin, C-peptide, glucagon, GLP-1 and proinsulin for assessing islet function and insulin-secretory kinetics.
Insulin-resistance-related adipokines: Adiponectin, leptin, resistin and visfatin to evaluate peripheral insulin sensitivity.
Signalling-pathway reagents: Antibodies targeting IRS and GLUT4 for PI3K-AKT mechanistic studies.
Complication-associated analytes: AGEs/RAGE, renal-function markers and lipid panels supporting nephropathy and macrovascular-complication research.
Inflammation and oxidative-stress panels: TNF-α, IL-6, MCP-1, SOD and MDA for profiling chronic inflammatory and oxidative damage.
Custom services are also available, including recombinant-protein production, monoclonal/polyclonal-antibody generation, ELISA/chemiluminescent-kit development and protein-antibody labelling. Reagents and animal-model services can be deployed together to build consistent, traceable experimental workflows.
The synergy between animal-model resources and detection reagents enables complete study workflows. In a typical type 2-diabetes drug-mechanism project, researchers can commission Cloud-Clone to build a high-fat-diet plus low-dose-STZ type 2-diabetes model, confirming successful modelling via blood-glucose, body-weight and oral-glucose-tolerance testing. Longitudinal monitoring of islet function and insulin sensitivity is performed using ELISA kits targeting insulin, C-peptide, GLP-1 and adiponectin. Post-mortem analyses include Oil-Red-O staining for hepatic steatosis, Masson staining for renal fibrosis, and biochemical measurement of renal-function and lipid parameters. Signalling-pathway investigation can be carried out using IRS- and GLUT4-targeting antibodies. Conducting modelling, biochemical assessment, pathological evaluation and mechanistic analysis under unified quality standards minimizes batch-to-batch variation caused by mixed-source supplies and avoids fragmented datasets. This integrated workflow supports both high-throughput compound screening and full pre-clinical-package generation. Products from Cloud-Clone have been cited in high-impact journals including Nature and The Lancet series, with publicly accessible reference lists available on the corporate website.
World Diabetes Day underscores the enormous global health burden imposed by diabetes and its complications. Reliable pre-clinical tools lay critical groundwork for translating basic discoveries into future therapies. Cloud-Clone combines well-characterized diabetic animal models, comprehensive metabolic-research reagents and flexible custom services to deliver robust technical support for metabolic-disease investigators worldwide.

SuKi Duan
CLOUD-CLONE CORP.WUHAN
Visit us on social media:
LinkedIn
Instagram
TikTok
X

Legal Disclaimer:

EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Media gallery

About The Author